A phase II trial of extended induction galiximab (anti-CD80 monoclonal antibody) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Jan 2018 Results (n=61) assessing safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL) were published in the Annals of Oncology.
06 Dec 2016 Pooled retrospective analysis (n=174) of this trial and two other trials (see NCT00553501 and NCT01145495) evaulating effects of early progression of disease was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
29 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com